HRP20151128T1 - Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze - Google Patents

Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze Download PDF

Info

Publication number
HRP20151128T1
HRP20151128T1 HRP20151128TT HRP20151128T HRP20151128T1 HR P20151128 T1 HRP20151128 T1 HR P20151128T1 HR P20151128T T HRP20151128T T HR P20151128TT HR P20151128 T HRP20151128 T HR P20151128T HR P20151128 T1 HRP20151128 T1 HR P20151128T1
Authority
HR
Croatia
Prior art keywords
formula
compound
represent
imidazo
thiadiazol
Prior art date
Application number
HRP20151128TT
Other languages
English (en)
Croatian (hr)
Inventor
Paolo Pevarello
Ana María GARCÍA COLLAZO
Ana Belén GARCÍA GARCÍA
Original Assignee
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii filed Critical Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii
Publication of HRP20151128T1 publication Critical patent/HRP20151128T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20151128TT 2007-09-27 2008-09-29 Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze HRP20151128T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07381066 2007-09-27
EP08806437.3A EP2193133B1 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors
PCT/GB2008/003287 WO2009040552A2 (en) 2007-09-27 2008-09-29 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
HRP20151128T1 true HRP20151128T1 (hr) 2015-11-20

Family

ID=39092755

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151128TT HRP20151128T1 (hr) 2007-09-27 2008-09-29 Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze

Country Status (13)

Country Link
US (1) US8563550B2 (enExample)
EP (1) EP2193133B1 (enExample)
JP (1) JP5410431B2 (enExample)
CN (1) CN101878219B (enExample)
CY (1) CY1116882T1 (enExample)
DK (1) DK2193133T3 (enExample)
ES (1) ES2548768T3 (enExample)
HR (1) HRP20151128T1 (enExample)
HU (1) HUE025976T2 (enExample)
PL (1) PL2193133T3 (enExample)
PT (1) PT2193133E (enExample)
SI (1) SI2193133T1 (enExample)
WO (1) WO2009040552A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ606294A (en) 2005-07-25 2014-09-26 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8563550B2 (en) 2007-09-27 2013-10-22 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazolothiadiazoles for use as protein kinase inhibitors
MX340204B (es) 2008-04-11 2016-06-30 Emergent Product Dev Seattle Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
JP2011529456A (ja) * 2008-07-29 2011-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング イミダゾチアジアゾール誘導体
WO2010112874A1 (en) * 2009-04-02 2010-10-07 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
US20130029967A1 (en) 2009-09-24 2013-01-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
ES2986590T3 (es) 2010-06-14 2024-11-12 Scripps Research Inst Reprogramación de células hacia un nuevo destino
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
EP2682395A1 (en) 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
JP6483610B2 (ja) * 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック ５，５−ヘテロ芳香族抗感染症化合物
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
EP3848035B1 (en) 2015-12-10 2025-02-19 PTC Therapeutics, Inc. 1,4-disubstituted pyridazine compounds for treating huntington's disease
US20190119300A1 (en) * 2016-04-18 2019-04-25 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
EP3814360B8 (en) * 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
RS65727B1 (sr) 2018-06-27 2024-08-30 Ptc Therapeutics Inc Heterociklična i heteroaril jedinjenja za lečenje hantingtonove bolesti
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
BR112021002515A2 (pt) * 2018-08-21 2021-07-27 Kyorin Pharmaceutical Co., Ltd. derivado de anel heteroaromático bicíclico
CA3158333A1 (en) * 2019-10-21 2021-04-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN117203211B (zh) * 2021-11-29 2025-08-19 中国海洋大学 咪唑并噻唑衍生物及其制备方法与应用
CN114195736B (zh) * 2021-12-30 2023-08-04 浙江闰土染料有限公司 2-氨基-5-溴-1,3,4-噻二唑的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) * 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3208437A1 (de) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
AU7001396A (en) 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
MXPA03001189A (es) 2000-08-09 2004-05-14 Agouron Pharma Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
CA2510534C (en) 2002-12-18 2011-09-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JP2006527209A (ja) * 2003-06-13 2006-11-30 アエジェラ・セラピューティクス・インコーポレーテッド アシル化及び非−アシル化イミダゾ［２，１−ｂ］−１，３，４−チアジアゾール−２−スルホンアミド及びその使用
US20060135571A1 (en) * 2003-06-13 2006-06-22 Jaquith James B Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones
CA2610695A1 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US20090170845A1 (en) 2006-04-13 2009-07-02 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
WO2007136730A2 (en) 2006-05-21 2007-11-29 Steven Allen Carlson Systems and methods for hydrogen storage and generation
CN101037445A (zh) * 2007-04-14 2007-09-19 西北师范大学 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
EA200901488A1 (ru) 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
BRPI0812360A2 (pt) * 2007-05-21 2015-01-27 Sgx Pharmaceuticals Inc Compostos moduladores de quinase heterocíclica e método de modulação da atividade de uma proteína tirosina quinase
US8563550B2 (en) 2007-09-27 2013-10-22 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazolothiadiazoles for use as protein kinase inhibitors
JP2011529456A (ja) 2008-07-29 2011-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング イミダゾチアジアゾール誘導体

Also Published As

Publication number Publication date
US8563550B2 (en) 2013-10-22
US20110190289A1 (en) 2011-08-04
EP2193133A2 (en) 2010-06-09
PL2193133T3 (pl) 2016-01-29
CN101878219A (zh) 2010-11-03
WO2009040552A3 (en) 2009-05-22
EP2193133B1 (en) 2015-08-19
SI2193133T1 (sl) 2015-12-31
DK2193133T3 (en) 2015-10-05
WO2009040552A2 (en) 2009-04-02
PT2193133E (pt) 2015-10-22
CN101878219B (zh) 2014-04-02
JP5410431B2 (ja) 2014-02-05
JP2010540508A (ja) 2010-12-24
HUE025976T2 (en) 2016-05-30
ES2548768T3 (es) 2015-10-20
CY1116882T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
HRP20151128T1 (hr) Imidazolotiadiazoli za uporabu kao inhibitori protein kinaze
JP6517976B2 (ja) 炎症性障害の治療のための化合物及びその医薬組成物
AU2015371400B2 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20081341A1 (es) Inhibidores de la actividad de la akt
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
PE20060424A1 (es) Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
RU2013114771A (ru) Диамиды азетидинила как ингибиторы моноацилглицерол липазы
HRP20120830T1 (hr) Imidazolkarboksamidi
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
US20110053982A1 (en) Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
MX2007008781A (es) Compuestos farmaceuticos.
JP2014037426A5 (enExample)
JP2009534455A (ja) 医薬化合物
SG175079A1 (en) Substituted piperidines as ccr3 antagonists
AR077463A1 (es) Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
RU2011125314A (ru) Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
US20150126501A1 (en) Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist
PE20220964A1 (es) Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas